Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Nov;193(5):1630-9.
doi: 10.1016/j.ajog.2005.05.005.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial

Saundra S Buys  1 , Edward Partridge, Mark H Greene, Philip C Prorok, Douglas Reding, Thomas L Riley, Patricia Hartge, Richard M Fagerstrom, Lawrence R Ragard, David Chia, Grant Izmirlian, Mona Fouad, Christine C Johnson, John K Gohagan; PLCO Project Team
Affiliations
Randomized Controlled Trial

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial

Saundra S Buys et al. Am J Obstet Gynecol. 2005 Nov.

Erratum in

  • Am J Obstet Gynecol. 2005 Dec;193(6):2183-4

Abstract

Objective: Ovarian cancer screening with transvaginal ultrasound (TVU) and CA-125 was evaluated in the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial.

Study design: This was a randomized controlled trial of screening versus usual care. Baseline screening results are reported.

Results: Of 39,115 women randomized to receive screening, 28,816 received at least 1 test. Abnormal TVU was found in 1338 (4.7%), and abnormal CA-125 in 402 (1.4%). Twenty-nine neoplasms were identified (26 ovarian, 2 fallopian, and 1 primary peritoneal neoplasm). Nine were tumors of low malignant potential and 20 were invasive. The positive predictive value for invasive cancer was 3.7% for an abnormal CA-125, 1.0% for an abnormal TVU, and 23.5% if both tests were abnormal.

Conclusion: The effect of screening on ovarian cancer mortality in the PLCO cohort has yet to be evaluated and will require longer follow-up. Screening identified both early- and late-stage neoplasms, and the predictive value of both tests was relatively low.

PubMed Disclaimer

Publication types